NasdaqCM:NMRD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Nemaura Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NMRD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.4%

NMRD

-1.7%

US Medical Equipment

-0.8%

US Market


1 Year Return

-51.8%

NMRD

16.5%

US Medical Equipment

13.8%

US Market

Return vs Industry: NMRD underperformed the US Medical Equipment industry which returned 16.5% over the past year.

Return vs Market: NMRD underperformed the US Market which returned 13.8% over the past year.


Shareholder returns

NMRDIndustryMarket
7 Day-2.4%-1.7%-0.8%
30 Day-7.6%-3.3%-5.0%
90 Day-59.4%13.4%10.1%
1 Year-51.8%-51.8%17.5%16.5%16.4%13.8%
3 Year-92.0%-92.0%70.0%65.6%36.9%27.8%
5 Year-81.7%-81.7%139.5%121.3%85.0%64.2%

Price Volatility Vs. Market

How volatile is Nemaura Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nemaura Medical undervalued compared to its fair value and its price relative to the market?

39.73x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NMRD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NMRD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NMRD is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: NMRD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NMRD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NMRD is overvalued based on its PB Ratio (39.7x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Nemaura Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.4%

Forecasted Healthcare industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NMRD's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if NMRD's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NMRD's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if NMRD's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NMRD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Nemaura Medical performed over the past 5 years?

-28.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NMRD is currently unprofitable.

Growing Profit Margin: NMRD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NMRD is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.

Accelerating Growth: Unable to compare NMRD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NMRD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: NMRD has a negative Return on Equity (-204.49%), as it is currently unprofitable.


Next Steps

Financial Health

How is Nemaura Medical's financial position?


Financial Position Analysis

Short Term Liabilities: NMRD's short term assets ($8.6M) exceed its short term liabilities ($3.6M).

Long Term Liabilities: NMRD's short term assets ($8.6M) exceed its long term liabilities ($3.4M).


Debt to Equity History and Analysis

Debt Level: NMRD's debt to equity ratio (244%) is considered high.

Reducing Debt: Insufficient data to determine if NMRD's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NMRD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NMRD has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 36.4% each year.


Next Steps

Dividend

What is Nemaura Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NMRD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NMRD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NMRD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NMRD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NMRD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Faz Chowdhury (47 yo)

11.67yrs

Tenure

US$103,770

Compensation

Dr. Dewan Fazlul Hoque Chowdhury, also known as Faz, founded Nemaura Pharma Limited and also serves as its serves as its Chief Executive Officer. Dr. Chowdhury has been the Chairman, President and Chief Ex ...


CEO Compensation Analysis

Compensation vs Market: Faz's total compensation ($USD103.77K) is below average for companies of similar size in the US market ($USD603.09K).

Compensation vs Earnings: Faz's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Dewan Fazlul Chowdhury
Chairman11.67yrsUS$103.77k38.24%
$ 32.0m
Christopher Avery
Vice President of Global Business Operationsno datano datano data
Bashir Timol
Chief Business Officer & Director6.75yrsno data11.83%
$ 9.9m
Kathryn Farrar
Financial Controller0.58yrno datano data

2.4yrs

Average Tenure

46.5yo

Average Age

Experienced Management: NMRD's management team is considered experienced (2.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dewan Fazlul Chowdhury
Chairman11.67yrsUS$103.77k38.24%
$ 32.0m
Bashir Timol
Chief Business Officer & Director6.75yrsno data11.83%
$ 9.9m
Timothy Johnson
Independent Director3.17yrsUS$6.36kno data
Salim Natha
Independent Director3.17yrsUS$6.36k1.75%
$ 1.5m
Thomas Moore
Independent Director3.08yrsUS$6.36kno data

3.2yrs

Average Tenure

47yo

Average Age

Experienced Board: NMRD's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.


Top Shareholders

Company Information

Nemaura Medical Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nemaura Medical Inc.
  • Ticker: NMRD
  • Exchange: NasdaqCM
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$83.791m
  • Shares outstanding: 22.89m
  • Website: https://nemauramedical.com

Number of Employees


Location

  • Nemaura Medical Inc.
  • 57 West 57th Street
  • Manhattan
  • New York
  • New York
  • 10019
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NMRDNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDDec 2014
N18ABST (Boerse-Stuttgart)YesCommon SharesDEEURDec 2014

Biography

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device f ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/27 05:51
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.